1. Colilla, S, Crow, A, Petku, W, Singer, DE, Simon, T, Liu, X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142-1147. doi:10.1016/j.amjcard.2013.05.063.
Google Scholar | Crossref | Medline | ISI2. Lloyd-Jones, DM, Wang, TJ, Leip, EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042-1046. doi:10.1161/01.CIR.0000140263.20897.42.
Google Scholar | Crossref | Medline | ISI3. Jackson, SL, Tong, X, Yin, X, George, MG., Ritchey, MD. Emergency department, hospital inpatient, and mortality burden of atrial fibrillation in the United States, 2006 to 2014. Am J Cardiol. 2017;120(11):1966-1973. doi:10.1016/j.amjcard.2017.08.017.
Google Scholar | Crossref | Medline4. Wolf, PA, Abbott, RD, Kannel, WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988. doi:10.1161/01.str.22.8.983.
Google Scholar | Crossref | Medline | ISI5. Stewart, S, Hart, CL, Hole, DJ, McMurray, JJV. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113(5):359-364. doi:10.1016/s0002-9343(02)01236-6.
Google Scholar | Crossref | Medline | ISI6. Kannel, WB, Abbott, RD, Savage, DD, McNamara, PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306(17):1018-1022. doi:10.1056/NEJM198204293061703.
Google Scholar | Crossref | Medline | ISI7. January, CT, Wann, LS, Alpert, JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199-e267. doi:10.1161/CIR.0000000000000041.
Google Scholar | Crossref8. January, CT, Wann, LS, Calkins, H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104-132. doi:10.1016/j.jacc.2019.01.011.
Google Scholar | Crossref | Medline9. Hindricks, G, Potpara, T, Dagres, N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612.
Google Scholar | Crossref | Medline10. Hargrove, KL, Robinson, EE, Lusk, KA, Hughes, DW, Neff, LA, Fowler, AL. Comparison of sustained rate control in atrial fibrillation with rapid ventricular rate: metoprolol vs. Am J Emerg Med. 2021;40:15-19. doi:10.1016/j.ajem.2020.11.073.
Google Scholar | Crossref | Medline11. McGrath, P, Kersten, B, Chilbert, MR, Rusch, C, Nadler, M. Evaluation of metoprolol versus diltiazem for rate control of atrial fibrillation in the emergency department. Am J Emerg Med. 2020(20):S0735-S6757. doi:10.1016/j.ajem.2020.11.039.
Google Scholar | Crossref12. Nuñez Cruz, S, DeMott, JM, Peksa, GD, Slocum, GW. Evaluation of the blood pressure effects of diltiazem versus metoprolol in the acute treatment of atrial fibrillation with rapid ventricular rate. Am J Emerg Med. 2021;46:329-334. doi:10.1016/j.ajem.2020.10.003.
Google Scholar | Crossref | Medline13. Nicholson, J, Czosnowski, Q, Flack, T, Pang, PS, Billups, K. Hemodynamic comparison of intravenous push diltiazem versus metoprolol for atrial fibrillation rate control. Am J Emerg Med. 2020;38(9):1879-1883. doi:10.1016/j.ajem.2020.06.034.
Google Scholar | Crossref | Medline14. Hirschy, R, Ackerbauer, KA, Peksa, GD, O’Donnell, EP, DeMott, JM. Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction. Am J Emerg Med. 2019;37(1):80-84. doi:10.1016/j.ajem.2018.04.062.
Google Scholar | Crossref | Medline15. Hines, MC, Reed, BN, Ivaturi, V, et al. Diltiazem versus metoprolol for rate control in atrial fibrillation with rapid ventricular response in the emergency department. Am J Health Syst Pharm. 2016;73(24):2068-2076. doi:10.2146/ajhp160126.
Google Scholar | Crossref | Medline16. Fromm, C, Suau, SJ, Cohen, V, et al. Diltiazem vs. metoprolol in the management of atrial fibrillation or flutter with rapid ventricular rate in the emergency department. J Emerg Med. 2015;49(2):175-182. doi:10.1016/j.jemermed.2015.01.014.
Google Scholar | Crossref | Medline17. Demircan, C, Cikriklar, HI, Engindeniz, Z, et al. Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation. Emerg Med J. 2005;22(6):411-414. doi:10.1136/emj.2003.012047.
Google Scholar | Crossref | Medline | ISI18. Diltiazem hydrochloride injection (Cardizem) [package insert] . Bedford, OH: Bedford Laboratories; February 2007.
Google Scholar19. Metoprolol tartrate tablet and injection (Lopressor) [package insert] . East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2008.
Google Scholar20. Ross, AL, O’Sullivan, DM, Drescher, MJ, Krawczynski, MA. Comparison of weight-based dose vs. standard dose diltiazem in patients with atrial fibrillation presenting to the emergency department. J Emerg Med. 2016;51(4):440-446. doi:10.1016/j.jemermed.2016.05.036.
Google Scholar | Crossref | Medline21. Ward, SM, Radke, J, Calhoun, C, et al. Weight-based versus non-weight-based diltiazem dosing in the setting of atrial fibrillation with rapid ventricular response. Am J Emerg Med. 2020;38(11):2271-2276. doi:10.1016/j.ajem.2019.09.020.
Google Scholar | Crossref | Medline22. Lee, J, Kim, K, Lee, CC, et al. Low-dose diltiazem in atrial fibrillation with rapid ventricular response. Am J Emerg Med. 2011;29(8):849-854. doi:10.1016/j.ajem.2010.03.021.
Google Scholar | Crossref | Medline23. Diltiazem hydrochloride extended release tablet (Cardizem LA) [package insert] . Bridgewater, NJ: Baus ch Health; May 2019.
Google Scholar24. Metoprolol succinate extended release tablet (TOPROL-XL) [package insert] . Wilmington, DE: AstraZeneca LP; March 2006.
Google Scholar25. Yancy, CW, Jessup, M, Bozkurt, B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16)e:240-e327. doi:10.1161/CIR.0b013e31829e8776.
Google Scholar | Crossref26. Goldstein, RE, Boccuzzi, SJ, Cruess, D, Nattel, S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction: the Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83(1):52-60. doi:10.1161/01.cir.83.1.52.
Google Scholar | Crossref | Medline27. The Multicenter Diltiazem Postinfarction Trial Research Group . The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385-392. doi:10.1056/NEJM198808183190701.
Google Scholar | Crossref | Medline | ISI28. Figulla, HR, Gietzen, F, Zeymer, U, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy: results of the diltiazem in dilated cardiomyopathy trial. Circulation. 1996;94(3):346-352. doi:10.1161/01.cir.94.3.346.
Google Scholar | Crossref | Medline